Andrew Butcher is speaking on “Balancing cost effectiveness with economics – alleviate funding constraints on HTA approved drugs by managing diverging stakeholder perspectives.” CRA is also sponsoring the conference.
For more information on the event, click here.
CRA presents at AXS25 "GLP-1s: Riding the Wave of Innovative Medications"
Read the key takeaways here.